This study tests new treatments for Crohn's Disease, a condition that causes inflammation in the digestive tract. It involves two drugs, Vedolizumab and either Adalimumab or Ustekinumab. Participants will try these drugs together in Part A and then take Vedolizumab alone in Part B.

The study will have about 150 adults. In Part A, participants will receive a combination of drugs and continue to Part B if they show improvement. Each person will be followed for at least 26 weeks after the last treatment. The study will last about 76 weeks in total.

To join, you must have a confirmed diagnosis of Crohn's Disease and have tried other treatments that didn't work well. You cannot join if you have other bowel diseases or certain infections.

• The study lasts up to 76 weeks, including follow-ups.
• You must visit the clinic for regular check-ups and treatments.
• Safety and effectiveness of the treatments will be monitored.